TAZICEF

Product NDC
0409-5093
11-digit product format
004095093
Labeler code
0409
Product ID
0409-5093_3f749ee0-db14-4ed0-9056-d545a38bbe3b
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
CEFTAZIDIME
Dosage form
INJECTION, POWDER, FOR SOLUTION
Route
INTRAVENOUS
Labeler
Hospira, Inc.
Application
ANDA064032
Marketing category
ANDA
Marketing start
2006-04-05
Marketing end
2026-09-30
Substance
CEFTAZIDIME
Active strength
2 g/1
Pharmacologic classes
Cephalosporin Antibacterial [EPC], Cephalosporins [CS]
NDC exclude flag
No
Listing certified through
2026-12-31
Current FDA listing
Yes

Additional Listing Data#

Finished product
Yes
Brand name base
TAZICEF

Active Ingredients#

Ingredient, Strength table
IngredientStrength
CEFTAZIDIME2 g/1

Harmonized Identifiers#

Field, Values table
FieldValues
Unii9M416Z9QNR

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
fb7d24f2-fcd1-4dc6-b9d0-b1f65bfffab5Product name120150409

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0409-5093-11TAZICEF10 in 1 TRAYINJECTION, POWDER, FOR SOLUTION1029
0409-5093-14TAZICEF1 in 1 VIAL, PATENT DELIVERY SYSTEMINJECTION, POWDER, FOR SOLUTION129

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0409-5093-11EA - Each0409-509343dbc70f-7fb2-464f-b14f-896d7bb9d8bb12012-07-24
0409-5093-14EA - Each0409-50935e535c81-22f6-4d20-a211-ff259ae0702512019-08-06
0409-5093-51EA - Each0409-509315d8472a-b178-4f0c-b4c9-7448cf13cec112012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
CEFTAZIDIMEACTIVE INGREDIENT9M416Z9QNRTAZICEF (CEFTAZIDIME) INJECTION, POWDER, FOR SOLUTION [HOSPIRA, INC.]14
CEFTAZIDIME ANHYDROUSACTIVE MOIETYDZR1ENT301TAZICEF (CEFTAZIDIME) INJECTION, POWDER, FOR SOLUTION [HOSPIRA, INC.]14
SODIUM CARBONATEINACTIVE INGREDIENT45P3261C7TTAZICEF (CEFTAZIDIME) INJECTION, POWDER, FOR SOLUTION [HOSPIRA, INC.]14

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0409-5093TAZICEF (CEFTAZIDIME) INJECTION, POWDER, FOR SOLUTION [HOSPIRA, INC.]29Current NDC, Legacy NDC, 2 package rows20211103_9b73979c-c95a-4433-0a9d-f9cea3cb557f.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
1659283cefTAZidime 1 GM InjectionPSN9b73979c-c95a-4433-0a9d-f9cea3cb557f29
1659287cefTAZidime 2 GM InjectionPSN9b73979c-c95a-4433-0a9d-f9cea3cb557f29
1659292Tazicef 1 GM InjectionPSN9b73979c-c95a-4433-0a9d-f9cea3cb557f29
1659294Tazicef 2 GM InjectionPSN9b73979c-c95a-4433-0a9d-f9cea3cb557f29
1659292ceftazidime 1000 MG Injection [Tazicef]SBD9b73979c-c95a-4433-0a9d-f9cea3cb557f29
1659294ceftazidime 2000 MG Injection [Tazicef]SBD9b73979c-c95a-4433-0a9d-f9cea3cb557f29
1659283ceftazidime 1000 MG InjectionSCD9b73979c-c95a-4433-0a9d-f9cea3cb557f29
1659287ceftazidime 2000 MG InjectionSCD9b73979c-c95a-4433-0a9d-f9cea3cb557f29
1659283ceftazidime (as ceftazidime pentahydrate) 1000 MG InjectionSY9b73979c-c95a-4433-0a9d-f9cea3cb557f29
1659287ceftazidime (as ceftazidime pentahydrate) 2000 MG InjectionSY9b73979c-c95a-4433-0a9d-f9cea3cb557f29
1659283ceftazidime 1 GM InjectionSY9b73979c-c95a-4433-0a9d-f9cea3cb557f29
1659287ceftazidime 2 GM InjectionSY9b73979c-c95a-4433-0a9d-f9cea3cb557f29
1659292Tazicef 1000 MG InjectionSY9b73979c-c95a-4433-0a9d-f9cea3cb557f29
1659294Tazicef 2000 MG InjectionSY9b73979c-c95a-4433-0a9d-f9cea3cb557f29

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startMarketing endSampleExclude flagStatus
0409-5093-110040950931110 VIAL, PATENT DELIVERY SYSTEM in 1 TRAY (0409-5093-11) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, PATENT DELIVERY SYSTEM (0409-5093-14) 2006-04-050000-00-00NoNoCurrent
0409-5093-14004095093141 in 1 VIAL, PATENT DELIVERY SYSTEMHistorical